NCT07156682View on ClinicalTrials.gov

QL1706 Plus XELOX as Neoadjuvant Therapy for MSS/pMMR Clinical Stage III Colon Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

September 25, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2028

Conditions
Colon CancerMSS/pMMRQL1706
Interventions
DRUG

QL1706

neoadjuvant administered at a dose of 5 mg/kg, intravenous infusion, every three weeks (Q3W), on day 1 of each cycle, 4 cycles

DRUG

XELOX

Oxaliplatin 130 mg/m² by intravenous infusion on Day 1; Capecitabine 850-1000 mg/m² orally twice daily (morning and evening) from Day 1 to Day 14; 4 Cycles in total.

Trial Locations (1)

250012

Qilu hospital of Shandong University, Jinan

All Listed Sponsors
lead

Qilu Hospital of Shandong University

OTHER